Paraneoplastic Pemphigus Market
Industry: Healthcare
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Report Type: Ongoing
Report ID: PMRREP32133
Paraneoplastic pemphigus (PNP) is often paraneoplastic mucocutaneous blistering disease developed due to underlying malignancy. According to Ophanet, paraneoplastic pemphigus often affects 1 in 2,000 people, it is one of the rare form of skin disorder associated with underlying lymph proliferative disorders such as Castleman disease, chronic lymphotic leukemia, sarcoma, and non-Hodgkin’s lymphoma.
Blood test is the initial diagnostic test carried out. The signs like concurrent internal tumor, serum antibodies or polymorphic mucatenous erruption occurs in the pemphigus disorder which has no specific treatment other than the supportive treatment. Immunomodulatory and immunosuppressant are the active products utilized in paraneoplastic pemphigus treatment.
According to International Pemphigus and Pemphigoid Foundation, data estimated that in U.S. more than 2500 peoples were suffering from pemphigus incidence. While the global paraneoplastic pemphigus incidences was found to be more than 40,000 in 2017.
COVID-19 outbreak in December 2019, has affected the global economy that halted the operations of various enterprises and manufacturing facilities. Slow-down of the clinical development activities owing to COVID-19 pandemic are expected to hamper the paraneoplastic pemphigus market growth. The business across the world has encountered labor shortage, a lack of raw material, break on transportation which is projected to show short-term negative impact on the growth of paraneoplastic pemphigus market during the forecast period.
Increase in prevalence of paraneoplastic pemphigus diseases, and advancements in diagnostic technologies are expected to drive the global paraneoplastic pemphigus market growth. Rising healthcare expenditure and increasing investment in research and development activities are the few propellants of the global paraneoplastic pemphigus market growth. However, limited treatments availability for paraneoplastic pemphigus treatment, directs to increase interest in the research and development activities and projected to boost the paraneoplastic pemphigus market during the forecast period. Lack of awareness and the treatment cost are the factors that expects to hinder the paraneoplastic pemphigus market growth.
| Based on the treatment |
|
| Based on route of administration |
|
| Based on the distribution channel |
|
| Based on region |
|
The global paraneoplastic pemphigus market growth may rise at a substantial rate during the forecast period owing to rise in prevalence of paraneoplastic pemphigus disease. Based on the treatment segment, corticosteroids hold the highest share and remains the global standard to treat the paraneoplastic pemphigus disease. The corticosteroids includes prednisone and prednisolone that suppresses the immune system and prevents the inflammation in the body. Basically, corticosteroids are recommended in combination with the immunosupperssants. Based on the route of administration, oral route is mainly preferred, following the topical route. Hospital pharmacies is projected to lead the global paraneoplastic pemphigus market owing to the availability of the advanced facilities.
North America is anticipated to dominate the global paraneoplastic pemphigus market owing to rising geriatric population and advanced technologies. In addition, strong research and development activities with immense investment in the region will fuel the market growth.
Europe is the second lucrative region in the global market due to rise in geriatric and rising tobacco consumption among peoples. Asia-Pacific regions witness higher growth rate in paraneoplastic pemphigus market owing to rapid surge in population and increase in the healthcare expenditure. Other regions like Latin America and Middle East and Africa are emerging countries and expected to create least opportunities for paraneoplastic pemphigus market during the forecast period.
The major players contributing in paraneoplastic pemphigus market are, Novartis Pharmaceuticals, Sanofi S.A., Hoffmann-La-Roche, Pfizer Inc., GlaxoSmithKline LLC, Teva Pharmaceuticals, Principia Biopharma, Inc., Biogen, Inc., Argenx, Teligent Inc., Syntimmune, Almirall, and others.
The research report on paraneoplastic pemphigus market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on market provides analysis and information according to market segments such as treatment, route of administration, and distribution channel.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
To know more about delivery timeline for this report Contact Sales
